Clinical Research Directory

Inclusion Criteria: 1. Age ≥ 18 years, regardless of gender; 2. Supratentorial ICH confirmed by brain CT scan; 3. No disability in the community before ICH (premorbid mRS≤1); 4. Neurological deficits related to the hematoma, with NIHSS score ≥ 6 and single-limb motor item score ≥ 2; 5. GCS score ≥ 6; 6. Able to initiate the first dose of minocycline within 24 hours of onset; 7. Signed and dated informed consent. Exclusion Criteria: 1. Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs; 2. Allergy to tetracycline antibiotics; 3. Use of vitamin A derivatives or steroid therapy within the past 3 months; 4. Concomitant infection requiring antibiotic treatment at admission; 5. Planned surgical intervention; 6. Life expectancy of less than 6 months due to comorbid conditions; 7. Severe hepatic and renal dysfunction, or AST and/or ALT \>3 times the upper limit of reference range, or serum creatinine \>265 μmol/L (\> 3 mg/dL); 8. Bleeding tendency, including heparin use within the past 48 hours (APTT ≥ 35 s), oral warfarin (INR \> 2), platelet count \< 100 × 10⁹/L, or hereditary hemorrhagic diseases; 9. Known pregnancy or breastfeeding; 10. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial; 11. A high likelihood that the patient will not adhere to the study treatment and follow-up regimen; 12. Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.